The pharmaceuticals industry starts to recover, among the global TOP20 pharmaceutical enterprises,Only 1 company saw a decline in revenue over 24 years.. In contrast, there were 8 companies in 23 years, the gap is particularly obvious.These 20 pharmaceutical companies,Six companies achieved double-digit revenue growth., including AstraZeneca, Novartis, Eli Lilly, Novo Nordisk, Amgen, and Takeda. There are also5 companies with growth rates between 7% and 9%(MSD, Pfizer, BMS, Sanofi, CSL)。Next, let's take a specific look.First, to talk about the biggest winners, it has to be Eli Lilly and Novo Nordisk, who have capitalized on the GLP-1 trend. They have been the top performers for two consecutive years.The Fastest-Growing TOP Pharmaceutical Companies. According to the current trend, it should continue to lead in 25 years.Riding this wave of growth, Eli Lilly moved directly from 15th place five years ago to 9th place on the list, while Novo Nordisk also successfully jumped from 17th to 11th place.In fact, compared with 2023, the overall ranking of the top 20 pharmaceutical companies in 2024 has not changed much. The top five on the list remain Johnson & Johnson, Roche, Merck, Pfizer, and AbbVie. Moreover, these five pharmaceutical companies all achieved a small growth of 3%-7%. It is worth noting that in 2023, Pfizer and Roche experienced revenue declines of 41% and 7%, respectively, due to the depletion of the COVID-19 product dividend. Therefore, this recovery in growth is extremely important for both of them.However, there were also temporary dropouts. Sanofi and GSK were the only two companies whose rankings fell by more than 2 places. Sanofi, affected by the divestiture of its consumer healthcare business, dropped from 6th to 10th place. Due to sluggish growth in its vaccine business, GSK was overtaken by Eli Lilly and Novo Nordisk, falling from 10th place two years ago to 12th place.Finally, there is one more new change: AVENTIS BEHRING ASIA PACIFIC LIMITED, headquartered in Australia.（ CSL ）Breaking into the top 20 for the first time, replacing Sanofi, which had experienced three consecutive years of revenue decline.'%20fill='%23FFFFFF'%3E%3Crect%20x='249'%20y='126'%20width='1'%20height='1'%3E%3C/rect%3E%3C/g%3E%3C/g%3E%3C/svg%3E)
Disclaimer:This article is for information sharing only, and does not represent the position or viewpoint of Insight. It does not recommend or introduce any treatment plans. If necessary, please consult and contact正规医疗机构.
Editor：ccai
PR Article Coordination: WeChat insightxb
SubmissionWeChat: insightxb; Email: insight@dxy.cn
Diversified functions, traceable data……Insight Database Web Version Awaits Your Experience
Click to read the original text,ImmediatelyUnlock！
